In contrast, using syngeneic orthotopic murine tumor models, Michaelis et al. demonstrated, that treatment of tumor‐bearing mice with the TLR7/8 agonist R848 reduced tumor mass and improved survival.22 Here, TLR7 is linked to neoplasm.